{
    "summary": "__\n\nU.S. Department of Health & Human Services\n\n  Administration for Strategic Preparedness and Response\n\nBARDA Stakeholder Portal ________\n\n  * Featured\n\nProject NextGen FDA Approvals BARDA Strategic Plan\n\n  * COVID-19 Response\n\nResponse Timeline COVID-19 Portfolio MCM Capacity Partnerships\n\n  * BARDA Industry Day 2023\n  * BARDA\n\nBARDA Strategic Plan Working at BARDA FDA Approvals BARDA Target Product\nProfiles CBRN Programs Core Services Contract Management & Acquisition CBRN\nPrograms Detection, Diagnostics, & Devices Infrastructure DRIVe Influenza &\nEmerging Infectious Diseases Innovation Nonclinical Development Regulatory &\nQuality Affairs\n\n  * BARDA Broad Agency Announcement (BAA) Other Investment Areas\n\nSepsis REMM CHEMM\n\n  * Who We Are\n\nWho We Are Announcements & Media BARDA Research\n\n  * BARDA (current)\n  * Request A Meeting\n  * _search_\n  * __\n\nFeatured\n\n  \nProject NextGen\n\n  \nView the Products\n\n  \nLearn About the Event\n\nProject NextGen\n\nCOVID-19 Response\n\nResponse Timeline COVID-19 Portfolio MCM Capacity Partnerships\n\nBARDA Industry Day 2023\n\nBARDA\n\nBARDA Strategic Plan Working at BARDA FDA Approvals Target Product Profiles\n\nBARDA Programs\n\nCBRN Programs Core Services Contract Management & Acquisition Detection,\nDiagnostics & Devices Infrastructure DRIVe Influenza & Emerging Infectious\nDiseases Innovation Nonclinical Development Regulatory & Quality Affairs\n\nBARDA Broad Agency  \nAnnouncement (BAA)\n\nOther Investment Areas\n\nSepsis REMM CHEMM\n\nWho We Are\n\nAnnouncements & Media BARDA Research\n\nRequest A Meeting\n\n#### This link goes to a non-USG site\n\n\u00d7\n\nThis link goes to a non-USG site. This site may not have USG standard privacy\ncontrol. Click OK to proceed in a separate browser window.\n\nX\n\n## I WANT TO FIND\n\n  \nSearch  \n  \n\nFEATURED SEARCHES:\n\n  \n\nBARDA Announcements & Media Project NextGen TechWatch Broad Agency\nAnnouncements (BAA) BARDA Industry Day Coronavirus PRISM\n\n# Medical Countermeasures Capacity Partnerships\n\nBARDA\u2019s commitment to investing in pharmaceutical manufacturing and supply\nchain resilience  \n\n;\n\nBARDA Programs __\n\n  * BARDA\n  * __CBRN Programs __\n    * Antimicrobials\n    * Antivirals/Antitoxins\n    * Burn & Blast MCMs\n    * Chemical MCMs\n    * Rad/Nuc MCMs\n    * Vaccines\n  * Clinical Development\n  * __Contract Management & Acquisition\n  * Detection, Diagnostics, & Devices\n  * DRIVe\n  * __Innovation __\n    * Sepsis\n  * __Influenza & EID __\n    * COVID-19 Response\n    * Pandemic Vaccines and Adjuvants\n    * Therapeutics\n    * Vaccines Development\n  * Nonclinical Development\n  * Pharmaceutical\n\nCountermeasures &\n\nInfrastructure\n\n  * __Regulatory & Quality Affairs\n\n;\n\nBARDA\u2019s COVID-19\n\nDomestic MCM Manufacturing Capacity Strengthening\n\nMCM Manufacturing Capacity Strengthening\n\nBARDA is making critical investments to accelerate the expansion of domestic\nmanufacturing capacity for ancillary supplies (e.g., needles, syringes, vials)\nas part of our commitment to foster and expand domestic pharmaceutical\nmanufacturing.\n\nNext Generation Manufacturing Investments\n\nBARDA is making critical next-generation and continuous manufacturing\ninvestments to drive innovation in manufacturing.\n\nMCM Industrial Base Expansion\n\nBARDA is investing in the domestic industrial base to sustain the\nmanufacturing capacity for raw materials, critical ingredients, consumables,\nand facilities required to produce COVID-19 (and future) vaccines and\ntherapeutics.\n\nThis page is updated regularly, but may not include all awards\n\n  * All  \n(25)\n\n  * MCM Manufacturing  \nCapacity Strengthening (0)\n\n  * Next Generation Manufacturing   \nInvestments (3)\n\n  * MCM Industrial  \nBase Expansion (22)\n\n  * __\n\n### Corning Incorporated (Corning Pharmaceutical Technologies)\n\n#### Corning glass tubing and bulk vials\n\n\n\nLearn More\n\n  * __\n\n### Gerresheimer Glass Inc.\n\n#### Vials\n\n\n\nLearn More\n\n  * __\n\n### Croda\n\n#### Domestic capacity expansion of raw materials for lipid nanoparticle\ntechnology\n\n\n\nLearn More\n\n  * __\n\n### Jubilant HollisterStier LLC (JHS)\n\n#### Expansion of Aseptic Fill-Finish BSL-1 Capacity\n\n\n\nLearn More\n\n  * __\n\n### Evonik\n\n#### Domestic capacity expansion of raw materials for lipid nanoparticle\ntechnology\n\n\n\nLearn More\n\n  * __\n\n### TriLink BioTechnologies\n\n#### Domestic expansion of nucleoside triphosphate (NTPs) & capping reagent\nmanufacturing\n\n\n\nLearn More\n\n  * __\n\n### Exela Pharma Sciences, LLC\n\n#### Expansion of Aseptic Fill-Finish BSL-1 Capacity\n\n\n\nLearn More\n\n  * __\n\n### Stevanato Group (SG) dba OMPI of America, Inc.\n\n#### Vials\n\n\n\nLearn More\n\n  * __\n\n### Schott Pharma USA, Inc.\n\n#### Vials\n\n\n\nLearn More\n\n  * __\n\n### High Purity New England (HPNE)\n\n#### Single-Use Technology and Single-Use Systems\n\n\n\nLearn More\n\n  * __\n\n### Par Pharmaceutical, an Endo International company\n\n#### Expansion of Aseptic Fill-Finish BSL-2 Capacity\n\n\n\nLearn More\n\n  * __\n\n### Retractable Technologies, Inc\n\n#### Increasing U.S. Manufacturing Capacity of Essential Healthcare Supplies\n\n\n\nLearn More\n\n  * __\n\n### Meissner Filtration Products\n\n#### Biocontainer, Freeze Thaw and Filling Assemblies, Fluid Transfer and\nFiltration Sets\n\n\n\nLearn More\n\n  * __\n\n### Merck Sharp & Dohme Corp.\n\n#### Immediate Response COVID-19 Manufacturing Network\n\n\n\nLearn More\n\n  * __\n\n### The Texas A&M University System\n\n#### Capacity Expansion and Reservation Contract for TAMUS/Fujifilm\n\n\n\nLearn More\n\n  * __\n\n### Cytiva\n\n#### COVID-19 Vaccine Manufacturing\n\n\n\nLearn More\n\n  * __\n\n### Ology Bioservices, Inc.\n\n#### Reservation of SARS-COV-2 Fill and Finish Manufacturing Capacity\n\n\n\nLearn More\n\n  * __\n\n### Grand River Aseptic Manufacturing, Inc. (\u201cGRAM\u201d)\n\n#### Manufacture & Distribution of COVID-19 Vaccines/Therapeutics\n\n\n\nLearn More\n\n  * __\n\n### ICU Medical\n\n#### Expanding Domestic Production of Needles & Syringes\n\n\n\nLearn More\n\n  * __\n\n### Becton, Dickinson and Company USA\n\n#### Expanding Domestic Production of Needles & Syringes\n\n\n\nLearn More\n\n  * __\n\n### Colorado State University\n\n#### SolaVAX\u2122 is an inactivated virus vaccine platform\n\n\n\nLearn More\n\n  * __\n\n### Corning Pharmaceutical Technologies, Corning Incorporated\n\n#### Corning glass tubing, vials, and cartridges\n\n\n\nLearn More\n\n  * __\n\n### Snapdragon Chemistry Inc.\n\n#### Continuous Manufacturing for Ribonucleotide Triphosphates\n\n\n\nLearn More\n\n  * __\n\n### CIADM at Emergent Biosolutions\n\n#### CDMO Drug Substance and Drug Product Manufacturing Capacity and Expansion\n\n\n\nLearn More\n\n  * __\n\n### Phlow\n\n#### US Based Advanced Manufacturing for COVID-19 essential medicines and\nfuture threats\n\n\n\nLearn More\n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Corning Incorporated (Corning Pharmaceutical Technologies) USA\n\n**Product Name:** Corning glass tubing and bulk vials\n\n* * *\n\n**Description:**  \nThis award expands the domestic industrial base capacity of advanced, high-\nquality Corning glass tubing as well as converted vials to reduce supply chain\nrisk and ensure rapid delivery of medical countermeasures (MCMs).\n\n  \n\n* * *\n\n**Base Award Amount:** | $103,796,898.00 (September 13, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Gerresheimer Glass Inc. null\n\n**Product Name:** Vials\n\n* * *\n\n**Description:**  \nThis effort proposes vial manufacturing capacity expansion of Gerresheimer\nGlass\u2019 existing facility to address the shortage of domestic vial\nmanufacturing capacity and to secure national defense requirements for\nresponse to current and future pandemic threats.\n\n  \n\n* * *\n\n**Base Award Amount:** | $65,591,077.00 (August 3, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Croda USA\n\n**Product Name:** Domestic capacity expansion of raw materials for lipid\nnanoparticle technology\n\n* * *\n\n**Description:**  \nCroda will expand existing plant capacity of lipids to support the domestic\nmanufacturing supply chain for the lipid nanoparticle technology used in mRNA\nvaccine production.\n\n  \n\n* * *\n\n**Base Award Amount:** | $75,000,000 (June 17, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Jubilant HollisterStier LLC (JHS) USA\n\n**Product Name:** Expansion of Aseptic Fill-Finish BSL-1 Capacity\n\n* * *\n\n**Description:**  \nThis award will double the company\u2019s annual fill-finish capacity with the\naddition of two Biosafety Level 1 (BSL-1) lines equipped with state-of-the-art\ntechnology. The new lines will be high-speed commercial scale with multi-\nproduct formulation, filling, and finishing capacity for the manufacture of\nboth vaccines and therapeutics, including packaging and cold storage.\n\n  \n\n* * *\n\n**Base Award Amount:** | $149,684,100  (May 27, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Evonik USA\n\n**Product Name:** Domestic capacity expansion of raw materials for lipid\nnanoparticle technology\n\n* * *\n\n**Description:**  \nEvonik will expand domestic manufacturing capacity for critical lipids used in\nmRNA vaccine production.\n\n  \n\n* * *\n\n**Base Award Amount:** | $149,100,000 (May 20, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### TriLink BioTechnologies USA\n\n**Product Name:** Domestic expansion of nucleoside triphosphate (NTPs) &\ncapping reagent manufacturing\n\n* * *\n\n**Description:**  \nTriLink will expand its manufacturing capacity of nucleoside triphosphate\n(NTP) and capping reagents to support the domestic manufacturing supply chain\nfor mRNA vaccine production.\n\n  \n\n* * *\n\n**Base Award Amount:** | $38,819,837 (May 18, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Exela Pharma Sciences, LLC USA\n\n**Product Name:** Expansion of Aseptic Fill-Finish BSL-1 Capacity\n\n* * *\n\n**Description:**  \nThis award will expand and accelerate the company\u2019s existing domestic aseptic\nformulation, fill and finish manufacturing capacity. Exela will design, build\nand commission one Biosafety Level 1 (BSL-1) multi-product formulation,\nfilling and finishing operation for the manufacture of vaccine and therapeutic\nproducts. \u200b\n\n  \n\n* * *\n\n**Base Award Amount:** | $40,402,738  (May 5, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Stevanato Group (SG) dba OMPI of America, Inc. USA\n\n**Product Name:** Vials\n\n* * *\n\n**Description:**  \nThis effort proposes new construction of a domestic glass vial facility and\nrepresents the first U.S. location for this multinational vial producer.\nDomestic real property expansion will increase vial manufacturing capacity for\nbulk and ready-to-use vials to satisfy national defense purposes in response\nto current and future pandemic threats.\n\n  \n\n* * *\n\n**Base Award Amount:** | $94,484,412.00 (February 28, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Schott Pharma USA, Inc. USA\n\n**Product Name:** Vials\n\n* * *\n\n**Description:**  \nThis effort proposes vial manufacturing capacity expansion of Schott Pharma\u2019s\nexisting facility to address the need shortage for domestic vial manufacturing\ncapacity and to secure national defense requirements for response to current\nand future pandemic threats.\n\n  \n\n* * *\n\n**Base Award Amount:** | $42,491,087.00 (January 21, 2022)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### High Purity New England (HPNE) USA\n\n**Product Name:** Single-Use Technology and Single-Use Systems\n\n* * *\n\n**Description:**  \nHPNE will expand the manufacturing capacity of single-use assemblies, single\nuse pumps, 2D bags, and single-use mixing systems that are critical components\nin vaccine manufacturing in support of the COVID-19 response. The newly\nexpanded capacity is expected to be online in early 2023.\n\n  \n\n* * *\n\n**Base Award Amount:** | $15,000,000.00 (January 6, 2022)  \n---|---  \n  \n\n**Cost Share:** No\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Par Pharmaceutical, an Endo International company USA\n\n**Product Name:** Expansion of Aseptic Fill-Finish BSL-2 Capacity\n\n* * *\n\n**Description:**  \nThis award establishes a new domestic sterile fill-finish manufacturing asset\ncapable of processing products requiring Biosafety Level 2 (BSL-2)\ncontainment, including packaging and cold storage, and provides sterile fill-\nfinish manufacturing services to the U.S. government.\n\n  \n\n* * *\n\n**Base Award Amount:** | $89,998,664  (November 12, 2021)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Retractable Technologies, Inc USA\n\n**Product Name:** Increasing U.S. Manufacturing Capacity of Essential\nHealthcare Supplies\n\n* * *\n\n**Description:**  \nThe partnership between BARDA-JPEO and Retractable Technologies, Inc. supports\ncapacity expansion for the manufacturing of safety needles and syringes that\nare necessary to support the American healthcare system during the COVID-19\npandemic\n\n  \n\n* * *\n\n**Base Award Amount:** |  $53,664,286 (July 1, 2020)  \n---|---  \n**Mod/Option 1 Amount:** | $27,365,232.00 (May 13, 2021)  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Meissner Filtration Products USA\n\n**Product Name:** Biocontainer, Freeze Thaw and Filling Assemblies, Fluid\nTransfer and Filtration Sets\n\n* * *\n\n**Description:**  \nMeissner will expand domestic capacity for single-use systems manufacturing\nincluding biocontainer assemblies, bottle assemblies, fluid transfer sets,\nfiltration sets and filling assemblies that are critical components in vaccine\nmanufacturing in support of the COVID-19 response.\n\n  \n\n* * *\n\n**Base Award Amount:** | $13,392,790.00 (April 1, 2021)  \n---|---  \n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Merck Sharp & Dohme Corp. USA\n\n**Product Name:** Immediate Response COVID-19 Manufacturing Network\n\n* * *\n\n**Description:**  \nMerck will repurpose some of its facilities in the U.S. to support rapid,\nlarge-scale manufacturing of vaccines or therapeutics for use in public health\nemergencies including the current pandemic. The facilities will be available\nto produce Merck products against COVID-19 or to private sector partners\nworking with the federal government on the COVID-19 response, beginning with\nthe Johnson & Johnson vaccine.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $105,400,000.00 (March 1, 2021)  \n---|---  \n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### The Texas A&M University System USA\n\n**Product Name:** Capacity Expansion and Reservation Contract for\nTAMUS/Fujifilm\n\n* * *\n\n**Description:**  \nThrough this award, BARDA will reserve existing vaccine manufacturing capacity\nas well as expand manufacturing capacity at the Texas A&M CIADM, via a\nmodification to an existing award to Fujifilm Diosynth Biotechnologies. This\ninvestment is part of BARDA\u2019s work to strengthen domestic capacity to produce\nvaccines against COVID-19.\n\n  \n\n* * *\n\n**Base Award Amount:** |  264,693,063.00 (July 24, 2020)  \n---|---  \n**Mod/Option 1 Amount:** | $8,410,083.00 (November 24, 2020)  \n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Cytiva USA\n\n**Product Name:** COVID-19 Vaccine Manufacturing\n\n* * *\n\n**Description:**  \nCytiva will expand its existing domestic Continental US (CONUS) based\nmanufacturing capacity for pharmaceutical consumables and hardware products\nrequired in the manufacture of potential USG (BARDA and affiliated partners)\nCOVID-19 vaccines\n\n  \n\n* * *\n\n**Base Award Amount:** |  $31,190,000 (October 13, 2020)  \n---|---  \n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Ology Bioservices, Inc. USA\n\n**Product Name:** Reservation of SARS-COV-2 Fill and Finish Manufacturing\nCapacity\n\n* * *\n\n**Description:**  \nThis action will reserve production capacity for a total of approximately\n15.57 M vials to satisfy an urgent need for reserve domestic aseptic fill /\nfinish manufacturing capacity for critical vaccines and therapeutics that are\nbeing developed in response to COVID-19. It will help ensure an uninterrupted\nsupply throughout the COVID-19 campaign.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $106,300,002.00 (August 17, 2020)  \n---|---  \n  \n\nX\n\n#### Next Generation Manufacturing Investment\n\n__\n\n### Grand River Aseptic Manufacturing, Inc. (\u201cGRAM\u201d) USA\n\n**Product Name:** Manufacture & Distribution of COVID-19 Vaccines/Therapeutics\n\n* * *\n\n**Description:**  \nExpansion of Grand River Aseptic Manufacturing (\u201cGRAM\u201d)\u2019s domestic capacity to\nperform aseptic fill/finish services for a USG-selected COVID-19 vaccine(s) or\ntherapeutic products.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $1,600,000.00 (August 6, 2020)  \n---|---  \n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### ICU Medical USA\n\n**Product Name:** Expanding Domestic Production of Needles & Syringes\n\n* * *\n\n**Description:**  \nThe partnership between BARDA-JPEO and ICU Medical supports capacity expansion\nfor the manufacturing of safety needles and syringes that are necessary to\nsupport the American healthcare system during the COVID-19 pandemic.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $20,663,774 (July 11, 2020)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Becton, Dickinson and Company USA USA\n\n**Product Name:** Expanding Domestic Production of Needles & Syringes\n\n* * *\n\n**Description:**  \nThe partnership between BARDA-JPEO and Becton, Dickinson supports capacity\nexpansion for the manufacturing of safety needles and syringes that are\nnecessary to support the American healthcare system during the COVID-19\npandemic and for other public health emergencies.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $42,303,230 (July 1, 2020)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### Next Generation Manufacturing Investment\n\n__\n\n### Colorado State University USA\n\n**Product Name:** SolaVAX\u2122 is an inactivated virus vaccine platform\n\n* * *\n\n**Description:**  \nRiboflavin & UV light selectively inactivate virus particles by directed\ndamage to nucleic acids while preserving the integrity of proteins & viral\nantigens. Generated virus particles will contain all potential antigenic\ntargets for immune response for use in a vaccine without capacity for\nreplication post-infection.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $699,994 (June 23, 2020)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Corning Pharmaceutical Technologies, Corning Incorporated USA\n\n**Product Name:** Corning glass tubing, vials, and cartridges\n\n* * *\n\n**Description:**  \nTo expand the domestic industrial base capacity of advanced, high-quality\nCorning glass borosilicate tubing as well as domestic conversion of vials to\nreduce supply chain risk and ensure rapid delivery of medical countermeasures\n(MCMs).\n\n  \n\n* * *\n\n**Base Award Amount:** | $261,623,543.00 (June 5, 2020)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### Next Generation Manufacturing Investment\n\n__\n\n### Snapdragon Chemistry Inc. USA\n\n**Product Name:** Continuous Manufacturing for Ribonucleotide Triphosphates\n\n* * *\n\n**Description:**  \nRapidly scalable continuous manufacturing platform for the chemical synthesis\nand purification of ribonucleotide triphosphates (NPT) from shelf-stable\nribonucleotide.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $691,878 (May 29, 2020)  \n---|---  \n  \n\n**Cost Share:** Yes\n\n  \n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### CIADM at Emergent Biosolutions USA\n\n**Product Name:** CDMO Drug Substance and Drug Product Manufacturing Capacity\nand Expansion\n\n* * *\n\n**Description:**  \nEmergent BioSolutions will commit drug substance and drug product\nmanufacturing capacity valued at approximately $542.75 million for production\nof COVID-19 vaccine candidates through 2021, in addition to an investment of\napproximately $85.5 million for the rapid expansion of Emergent\u2019s contract\ndevelopment and manufacturing (CDMO) viral and non-viral drug product / fill-\nfinish capacity for vaccines and therapeutics.\n\n  \n\n**Unique Impact:**  \nEmergent BioSolutions will commit drug substance and drug product\nmanufacturing capacity valued at approximately $542.75 million for production\nof COVID-19 vaccine candidates through 2021, in addition to an investment of\napproximately $85.5 million for the rapid expansion of Emergent\u2019s contract\ndevelopment and manufacturing (CDMO) viral and non-viral drug product / fill-\nfinish capacity for vaccines and therapeutics.\n\n  \n\n* * *\n\n**Task Order:** |  $628,250,000 (May 30, 2020)  \n---|---  \n**Task Order:** | $20,000,000.00 (August 6, 2020)  \n**Task Order:** | $22,815,445.00 (March 24, 2021)  \n  \n\nProduct no longer supported\n\nX\n\n#### MCM Industrial Base Expansion\n\n__\n\n### Phlow USA\n\n**Product Name:** US Based Advanced Manufacturing for COVID-19 essential\nmedicines and future threats\n\n* * *\n\n**Description:**  \nPhlow pursues their mission of securing the national supply of essential\nmedicines through partnerships with pharmaceutical supply and manufacturing\norganizations including AMPAC Fine Chemicals, Civica Rx, and the Medicines for\nAll Institute at the Virginia Commonwealth University\u2019s College of\nEngineering.\n\n  \n\n**Unique Impact:**  \nPhlow pursues their mission of securing the national supply of essential\nmedicines through partnerships with pharmaceutical supply and manufacturing\norganizations including AMPAC Fine Chemicals, Civica Rx, and the Medicines for\nAll Institute at the Virginia Commonwealth University\u2019s College of\nEngineering.\n\n  \n\n* * *\n\n**Base Award Amount:** |  $360,284,721.00 (May 18, 2020)  \n---|---  \n  \n\nProduct no longer supported\n\n#### Navigation\n\n  * Home\n  * Announcements & Media\n  * Who We Are\n  * BARDA\n  * Working @ Barda\n\n#### Resources\n\n  * Website Disclaimers\n  * USA.gov\n  * No Fear Act\n  * Accessibility\n  * White House\n  * FOIA\n  * Vulnerability Disclosure Policy\n\n#### Popular\n\n  * Project NextGen\n  * BARDA Funding Opportunities\n  * BARDA TechWatch Program\n  * Guidance for Chemical Incidents\n  * View Products\n\n#### Social Media\n\n__________\n\nBe the first to know about BARDA news and new awards. Sign-up for our email\nannouncements:\n\nContact Our Webmaster  |   Get Adobe Reader  |   View Our Glossary  |   Send\nUs Feedback  |   Site Map\n\nThis is an official U.S. Government Web site managed by the U.S. Department of\nHealth & Human Services.\n\nMedicalCountermeasures.gov \u00a9 _2024_. Privacy Policy\n\n",
    "links": "[{\"link\": \"https://medicalcountermeasures.gov/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/nextgen/\", \"text\": \"Project NextGen\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/fdaapprovals/\", \"text\": \"FDA Approvals\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/strategic-plan/\", \"text\": \"BARDA Strategic Plan\"}, {\"link\": \"https://medicalcountermeasures.gov/app/barda/COVIDTimeline.aspx\", \"text\": \"Response Timeline\"}, {\"link\": \"https://medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx\", \"text\": \"COVID-19 Portfolio\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/coronavirus/pharmaceutical-manufacturing-in-america\", \"text\": \"MCM Capacity  Partnerships\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-industry-day-2023/\", \"text\": \"BARDA Industry Day 2023\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/strategic-plan/\", \"text\": \"BARDA Strategic Plan\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/working-at-barda/\", \"text\": \"Working at BARDA\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/fdaapprovals/\", \"text\": \"FDA Approvals\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/tpp\", \"text\": \"BARDA Target Product Profiles\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn\", \"text\": \"CBRN Programs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/core-services\", \"text\": \"Core Services\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cma\", \"text\": \"Contract Management & Acquisition\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/\", \"text\": \"CBRN Programs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dddi/\", \"text\": \"Detection, Diagnostics, & Devices Infrastructure\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/\", \"text\": \"Influenza & Emerging Infectious Diseases\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation\", \"text\": \"Innovation\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dncd/\", \"text\": \"Nonclinical Development\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/rqa/\", \"text\": \"Regulatory & Quality Affairs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-baa/\", \"text\": \"BARDA Broad Agency Announcement (BAA)\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation/barda-sepsis-awareness-month\", \"text\": \"Sepsis\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/whoweare/\", \"text\": \"Who We Are\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/\", \"text\": \"Announcements & Media\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/research/\", \"text\": \"BARDA Research\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/\", \"text\": \"Request A Meeting\"}, {\"link\": \"https://medicalcountermeasures.gov/nextgen/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/fdaapprovals/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-industry-day-2023/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/nextgen/\", \"text\": \"Project NextGen\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-covid-19-response/\", \"text\": \"COVID-19 Response\"}, {\"link\": \"https://medicalcountermeasures.gov/app/barda/COVIDTimeline.aspx\", \"text\": \"Response Timeline\"}, {\"link\": \"https://medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx\", \"text\": \"COVID-19 Portfolio\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/coronavirus/pharmaceutical-manufacturing-in-america\", \"text\": \"MCM Capacity  Partnerships\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-industry-day-2023\", \"text\": \"BARDA Industry Day 2023\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/\", \"text\": \"BARDA\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/strategic-plan/\", \"text\": \"BARDA Strategic Plan\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/working-at-barda/\", \"text\": \"Working at BARDA\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/fdaapprovals\", \"text\": \"FDA Approvals\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/tpp\", \"text\": \"Target Product Profiles\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn\", \"text\": \"CBRN Programs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/core-services\", \"text\": \"Core Services\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cma\", \"text\": \"Contract Management & Acquisition\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dddi\", \"text\": \"Detection, Diagnostics & Devices Infrastructure\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/\", \"text\": \"Influenza & Emerging Infectious Diseases\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation\", \"text\": \"Innovation\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dncd/\", \"text\": \"Nonclinical Development\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/rqa/\", \"text\": \"Regulatory & Quality Affairs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-baa/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation/barda-sepsis-awareness-month\", \"text\": \"Sepsis\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/whoweare/\", \"text\": \"Who We Are\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/\", \"text\": \"Announcements & Media\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/research/\", \"text\": \"BARDA Research\"}, {\"link\": \"https://medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/\", \"text\": \"Request A Meeting\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/\", \"text\": \"BARDA\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/antibacterials\", \"text\": \"Antimicrobials\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/antivirals-antitoxins\", \"text\": \"Antivirals/Antitoxins\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/burn-blast\", \"text\": \"Burn & Blast MCMs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/chemical-medical-countermeasures\", \"text\": \"Chemical MCMs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/radiological-and-nuclear-countermeasures\", \"text\": \"Rad/Nuc MCMs\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/vaccines\", \"text\": \"Vaccines\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/core-services\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cma/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dddi\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/advancing-innovation/barda-sepsis-awareness-month\", \"text\": \"Sepsis\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-covid-19-response/\", \"text\": \"COVID-19 Response\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/pandemic-vaccines-adjuvants/\", \"text\": \"Pandemic Vaccines and Adjuvants\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/therapeutics/\", \"text\": \"Therapeutics\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/vaccine-development/\", \"text\": \"Vaccines Development\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/dncd/\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/coronavirus/pharmaceutical-manufacturing-in-america\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/rqa\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/rti/\", \"text\": \"$53,664,286 (July 1, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2021/merckjj/\", \"text\": \"$105,400,000.00 (March 1, 2021)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/tamus/\", \"text\": \"264,693,063.00 (July 24, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/cytiva/\", \"text\": \"$31,190,000 (October 13, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/ologybio/\", \"text\": \"$106,300,002.00 (August 17, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/grandriver/\", \"text\": \"$1,600,000.00 (August 6, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/smiths\", \"text\": \"$20,663,774 (July 11, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/bd/\", \"text\": \"$42,303,230 (July 1, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/csu\", \"text\": \"$699,994 (June 23, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/snapdragon/\", \"text\": \" $691,878 (May 29, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/emergent-manufacturing\", \"text\": \"$628,250,000 (May 30, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/2020/phlow-us-manufacturing/\", \"text\": \"$360,284,721.00 (May 18, 2020)\"}, {\"link\": \"https://medicalcountermeasures.gov/\", \"text\": \"Home\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom/\", \"text\": \"Announcements & Media\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/whoweare/\", \"text\": \"Who We Are\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/\", \"text\": \"BARDA\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/working-at-barda/\", \"text\": \"Working @ Barda\"}, {\"link\": \"https://medicalcountermeasures.gov/websitedisclaimers/\", \"text\": \"Website Disclaimers\"}, {\"link\": \"https://medicalcountermeasures.gov/nextgen\", \"text\": \"Project NextGen\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/barda-baa/\", \"text\": \"BARDA Funding Opportunities\"}, {\"link\": \"https://medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/\", \"text\": \"BARDA TechWatch Program\"}, {\"link\": \"https://medicalcountermeasures.gov/barda/cbrn/prism/\", \"text\": \"Guidance for Chemical Incidents\"}, {\"link\": \"https://medicalcountermeasures.gov/newsroom#products\", \"text\": \"View Products\"}, {\"link\": \"https://medicalcountermeasures.gov/rss_feeds/barda.xml\", \"text\": \"\"}, {\"link\": \"https://medicalcountermeasures.gov/contactus/\", \"text\": \"Contact Our Webmaster\"}, {\"link\": \"https://medicalcountermeasures.gov/glossary/\", \"text\": \"View Our Glossary\"}, {\"link\": \"https://medicalcountermeasures.gov/feedback/\", \"text\": \"Send Us Feedback\"}, {\"link\": \"https://medicalcountermeasures.gov/sitemap/\", \"text\": \"Site Map\"}, {\"link\": \"https://medicalcountermeasures.gov/privacypolicy/\", \"text\": \"Privacy Policy\"}]",
    "priceAndPlans": "Error: Timeout 30000ms exceeded. =========================== logs\n=========================== navigating to\n\"http://web.archive.org/web/20240116002608/https://medicalcountermeasures.gov/\",\nwaiting until \"load\"\n============================================================\n\n"
}